BackMarksans Pharma Limited Overview

Marksans Pharma Limited Receivables

Latest receivables for MARKSANS.NS: $7.6B.

Get informed when a big investor buys or sells

+ Follow
Receivables
$7.57B
↑ 25.58% YoYΔ $1.54B vs prior year quarter

Peer trimmed avg / median

Loading

Marksans Pharma Limited Receivables History

Loading

Marksans Pharma Limited vs. peers: Receivables Comparison

Loading

Marksans Pharma Limited Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Marksans Pharma Limited (MARKSANS.NS) FAQ

As of the most recent data (September 2026), MARKSANS.NS shows a receivables of $7.6B. That compares with $6B in the prior-year period — up 25.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, MARKSANS.NS's receivables is now $7.6B (was $6B) — a 25.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Marksans Pharma Limited is outperforming or lagging.

Tracking MARKSANS.NS's receivables over time shows whether Marksans Pharma Limited is scaling, shrinking, or reshaping that part of the business. The current reading is $7.6B That compares with $6B in the prior-year period — up 25.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Marksans Pharma Limited's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $7.6B) with ownership activity and broader fundamentals.

Questions & Answers